Oncogenes in male breast cancer
The objective of this study was to assess the degree of expression and prognostic significance of c-erbB-2, p53, and bcl-2 in male breast cancer (MBC). Thirty male patients with the diagnosis of adenocarcinoma of the breast were studied retrospectively. All patients underwent surgery; c-erbB-2, p53,...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical oncology 2003-06, Vol.26 (3), p.259-261 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 261 |
|---|---|
| container_issue | 3 |
| container_start_page | 259 |
| container_title | American journal of clinical oncology |
| container_volume | 26 |
| creator | IDELEVICH, Efraim MOZES, Marta BEN-BARUCH, Noa HUSZAR, Monica KRUGLIKOVA, Anna KATSNELSON, Rivka SHANI, Adi |
| description | The objective of this study was to assess the degree of expression and prognostic significance of c-erbB-2, p53, and bcl-2 in male breast cancer (MBC). Thirty male patients with the diagnosis of adenocarcinoma of the breast were studied retrospectively. All patients underwent surgery; c-erbB-2, p53, and bcl-2 were immunohistochemically stained on sections from formalin-fixed, paraffin-embedded tissues. Seventeen (56.7%) of the 30 cases of MBC were bcl-2 positive. Few specimens were found positive for c-erbB-2 (6.7%) and p53 (6.7%). The 5-year survival rate was marginally better for those patients with tumors staining positively for bcl-2 (p = 0.05). It was impossible to estimate the association between survival rate and p53 and c-erbB-2 expression because of the small number of positively stained specimens. In this study, only bcl-2 showed marginal association to other tumor parameters and a trend toward a better 5-year survival rate. At present there is inadequate evidence to support the use of molecular markers as independent prognostic markers in MBC. |
| doi_str_mv | 10.1097/01.COC.0000020582.25017.5D |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73349326</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73349326</sourcerecordid><originalsourceid>FETCH-LOGICAL-c345t-7f20515bf58e13319c7f8d676a51400b9f975748c3a5250f738de7e0d3ff8a833</originalsourceid><addsrcrecordid>eNpFkMtOwzAQRS0EoqXwCxAhwS7BzsQZmx0KT6lSNyCxsxzHRkF5FLtd8Pe4NFJnM5tz74wOIdeMZoxKvKMsq1ZVRneTUy7yLOeUYcYfj8icccC04PB5TOY0R0wBIZ-RsxC-I85LiqdkxnKUJZflnFytBjN-2cGGpB2SXnc2qb3VYZMYPRjrz8mJ012wF9NekI_np_fqNV2uXt6qh2VqoOCbFF18hPHacWEZAJMGnWhKLDVnBaW1dBI5FsKA5vFZhyAai5Y24JzQAmBBbve9az_-bG3YqL4NxnadHuy4DQoBCgl5GcH7PWj8GIK3Tq1922v_qxhVOz2KMhX1qIMe9a9H8ccYvpyubOveNofo5CMCNxOgg9Gd81FCGw5cIWMlLeEPJklrNw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73349326</pqid></control><display><type>article</type><title>Oncogenes in male breast cancer</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>IDELEVICH, Efraim ; MOZES, Marta ; BEN-BARUCH, Noa ; HUSZAR, Monica ; KRUGLIKOVA, Anna ; KATSNELSON, Rivka ; SHANI, Adi</creator><creatorcontrib>IDELEVICH, Efraim ; MOZES, Marta ; BEN-BARUCH, Noa ; HUSZAR, Monica ; KRUGLIKOVA, Anna ; KATSNELSON, Rivka ; SHANI, Adi</creatorcontrib><description>The objective of this study was to assess the degree of expression and prognostic significance of c-erbB-2, p53, and bcl-2 in male breast cancer (MBC). Thirty male patients with the diagnosis of adenocarcinoma of the breast were studied retrospectively. All patients underwent surgery; c-erbB-2, p53, and bcl-2 were immunohistochemically stained on sections from formalin-fixed, paraffin-embedded tissues. Seventeen (56.7%) of the 30 cases of MBC were bcl-2 positive. Few specimens were found positive for c-erbB-2 (6.7%) and p53 (6.7%). The 5-year survival rate was marginally better for those patients with tumors staining positively for bcl-2 (p = 0.05). It was impossible to estimate the association between survival rate and p53 and c-erbB-2 expression because of the small number of positively stained specimens. In this study, only bcl-2 showed marginal association to other tumor parameters and a trend toward a better 5-year survival rate. At present there is inadequate evidence to support the use of molecular markers as independent prognostic markers in MBC.</description><identifier>ISSN: 0277-3732</identifier><identifier>EISSN: 1537-453X</identifier><identifier>DOI: 10.1097/01.COC.0000020582.25017.5D</identifier><identifier>PMID: 12796596</identifier><identifier>CODEN: AJCODI</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Aged ; Aged, 80 and over ; Biological and medical sciences ; Biomarkers, Tumor - metabolism ; Breast Neoplasms, Male - metabolism ; Breast Neoplasms, Male - mortality ; Breast Neoplasms, Male - pathology ; Carcinoma, Ductal, Breast - metabolism ; Carcinoma, Ductal, Breast - mortality ; Carcinoma, Ductal, Breast - pathology ; Humans ; Male ; Medical sciences ; Middle Aged ; Prognosis ; Proto-Oncogene Proteins c-bcl-2 - metabolism ; Receptor, ErbB-2 - metabolism ; Retrospective Studies ; Survival Analysis ; Tumor Suppressor Protein p53 - metabolism</subject><ispartof>American journal of clinical oncology, 2003-06, Vol.26 (3), p.259-261</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c345t-7f20515bf58e13319c7f8d676a51400b9f975748c3a5250f738de7e0d3ff8a833</citedby><cites>FETCH-LOGICAL-c345t-7f20515bf58e13319c7f8d676a51400b9f975748c3a5250f738de7e0d3ff8a833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14902006$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12796596$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>IDELEVICH, Efraim</creatorcontrib><creatorcontrib>MOZES, Marta</creatorcontrib><creatorcontrib>BEN-BARUCH, Noa</creatorcontrib><creatorcontrib>HUSZAR, Monica</creatorcontrib><creatorcontrib>KRUGLIKOVA, Anna</creatorcontrib><creatorcontrib>KATSNELSON, Rivka</creatorcontrib><creatorcontrib>SHANI, Adi</creatorcontrib><title>Oncogenes in male breast cancer</title><title>American journal of clinical oncology</title><addtitle>Am J Clin Oncol</addtitle><description>The objective of this study was to assess the degree of expression and prognostic significance of c-erbB-2, p53, and bcl-2 in male breast cancer (MBC). Thirty male patients with the diagnosis of adenocarcinoma of the breast were studied retrospectively. All patients underwent surgery; c-erbB-2, p53, and bcl-2 were immunohistochemically stained on sections from formalin-fixed, paraffin-embedded tissues. Seventeen (56.7%) of the 30 cases of MBC were bcl-2 positive. Few specimens were found positive for c-erbB-2 (6.7%) and p53 (6.7%). The 5-year survival rate was marginally better for those patients with tumors staining positively for bcl-2 (p = 0.05). It was impossible to estimate the association between survival rate and p53 and c-erbB-2 expression because of the small number of positively stained specimens. In this study, only bcl-2 showed marginal association to other tumor parameters and a trend toward a better 5-year survival rate. At present there is inadequate evidence to support the use of molecular markers as independent prognostic markers in MBC.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Breast Neoplasms, Male - metabolism</subject><subject>Breast Neoplasms, Male - mortality</subject><subject>Breast Neoplasms, Male - pathology</subject><subject>Carcinoma, Ductal, Breast - metabolism</subject><subject>Carcinoma, Ductal, Breast - mortality</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Proto-Oncogene Proteins c-bcl-2 - metabolism</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><issn>0277-3732</issn><issn>1537-453X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtOwzAQRS0EoqXwCxAhwS7BzsQZmx0KT6lSNyCxsxzHRkF5FLtd8Pe4NFJnM5tz74wOIdeMZoxKvKMsq1ZVRneTUy7yLOeUYcYfj8icccC04PB5TOY0R0wBIZ-RsxC-I85LiqdkxnKUJZflnFytBjN-2cGGpB2SXnc2qb3VYZMYPRjrz8mJ012wF9NekI_np_fqNV2uXt6qh2VqoOCbFF18hPHacWEZAJMGnWhKLDVnBaW1dBI5FsKA5vFZhyAai5Y24JzQAmBBbve9az_-bG3YqL4NxnadHuy4DQoBCgl5GcH7PWj8GIK3Tq1922v_qxhVOz2KMhX1qIMe9a9H8ccYvpyubOveNofo5CMCNxOgg9Gd81FCGw5cIWMlLeEPJklrNw</recordid><startdate>20030601</startdate><enddate>20030601</enddate><creator>IDELEVICH, Efraim</creator><creator>MOZES, Marta</creator><creator>BEN-BARUCH, Noa</creator><creator>HUSZAR, Monica</creator><creator>KRUGLIKOVA, Anna</creator><creator>KATSNELSON, Rivka</creator><creator>SHANI, Adi</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030601</creationdate><title>Oncogenes in male breast cancer</title><author>IDELEVICH, Efraim ; MOZES, Marta ; BEN-BARUCH, Noa ; HUSZAR, Monica ; KRUGLIKOVA, Anna ; KATSNELSON, Rivka ; SHANI, Adi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c345t-7f20515bf58e13319c7f8d676a51400b9f975748c3a5250f738de7e0d3ff8a833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Breast Neoplasms, Male - metabolism</topic><topic>Breast Neoplasms, Male - mortality</topic><topic>Breast Neoplasms, Male - pathology</topic><topic>Carcinoma, Ductal, Breast - metabolism</topic><topic>Carcinoma, Ductal, Breast - mortality</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Proto-Oncogene Proteins c-bcl-2 - metabolism</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>IDELEVICH, Efraim</creatorcontrib><creatorcontrib>MOZES, Marta</creatorcontrib><creatorcontrib>BEN-BARUCH, Noa</creatorcontrib><creatorcontrib>HUSZAR, Monica</creatorcontrib><creatorcontrib>KRUGLIKOVA, Anna</creatorcontrib><creatorcontrib>KATSNELSON, Rivka</creatorcontrib><creatorcontrib>SHANI, Adi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>IDELEVICH, Efraim</au><au>MOZES, Marta</au><au>BEN-BARUCH, Noa</au><au>HUSZAR, Monica</au><au>KRUGLIKOVA, Anna</au><au>KATSNELSON, Rivka</au><au>SHANI, Adi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oncogenes in male breast cancer</atitle><jtitle>American journal of clinical oncology</jtitle><addtitle>Am J Clin Oncol</addtitle><date>2003-06-01</date><risdate>2003</risdate><volume>26</volume><issue>3</issue><spage>259</spage><epage>261</epage><pages>259-261</pages><issn>0277-3732</issn><eissn>1537-453X</eissn><coden>AJCODI</coden><abstract>The objective of this study was to assess the degree of expression and prognostic significance of c-erbB-2, p53, and bcl-2 in male breast cancer (MBC). Thirty male patients with the diagnosis of adenocarcinoma of the breast were studied retrospectively. All patients underwent surgery; c-erbB-2, p53, and bcl-2 were immunohistochemically stained on sections from formalin-fixed, paraffin-embedded tissues. Seventeen (56.7%) of the 30 cases of MBC were bcl-2 positive. Few specimens were found positive for c-erbB-2 (6.7%) and p53 (6.7%). The 5-year survival rate was marginally better for those patients with tumors staining positively for bcl-2 (p = 0.05). It was impossible to estimate the association between survival rate and p53 and c-erbB-2 expression because of the small number of positively stained specimens. In this study, only bcl-2 showed marginal association to other tumor parameters and a trend toward a better 5-year survival rate. At present there is inadequate evidence to support the use of molecular markers as independent prognostic markers in MBC.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>12796596</pmid><doi>10.1097/01.COC.0000020582.25017.5D</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-3732 |
| ispartof | American journal of clinical oncology, 2003-06, Vol.26 (3), p.259-261 |
| issn | 0277-3732 1537-453X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73349326 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Aged Aged, 80 and over Biological and medical sciences Biomarkers, Tumor - metabolism Breast Neoplasms, Male - metabolism Breast Neoplasms, Male - mortality Breast Neoplasms, Male - pathology Carcinoma, Ductal, Breast - metabolism Carcinoma, Ductal, Breast - mortality Carcinoma, Ductal, Breast - pathology Humans Male Medical sciences Middle Aged Prognosis Proto-Oncogene Proteins c-bcl-2 - metabolism Receptor, ErbB-2 - metabolism Retrospective Studies Survival Analysis Tumor Suppressor Protein p53 - metabolism |
| title | Oncogenes in male breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T08%3A07%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oncogenes%20in%20male%20breast%20cancer&rft.jtitle=American%20journal%20of%20clinical%20oncology&rft.au=IDELEVICH,%20Efraim&rft.date=2003-06-01&rft.volume=26&rft.issue=3&rft.spage=259&rft.epage=261&rft.pages=259-261&rft.issn=0277-3732&rft.eissn=1537-453X&rft.coden=AJCODI&rft_id=info:doi/10.1097/01.COC.0000020582.25017.5D&rft_dat=%3Cproquest_cross%3E73349326%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73349326&rft_id=info:pmid/12796596&rfr_iscdi=true |